Weekday mode: Asia was live/near close; Europe was pre-open. U.S. futures, rates, FX and commodities are indicative snapshots. The 08:30 Italy cutoff precedes U.S. July retail sales at 08:30 ET / 14:30 Italy and Michigan sentiment later in the U.S. morning.
| Market | Latest / move | Session represented | Read-through |
|---|---|---|---|
| U.S. index futures | Little changed; Dow +20 points | CNBC around 08:05 CEST | No strong overnight edge before retail sales |
| Nikkei 225 | 68,703.28 · +0.58% | Live/near close | AI-chip strength; yen/intervention risk persists |
| Kospi | +1.14% | CNBC live snapshot | Further chip-led gain, slower than Thursday |
| Hang Seng | 25,144.85 · −0.99% | Live | Asia not uniformly risk-on |
| Shanghai Composite | 3,925.22 · −0.04% | Live | Flat-to-soft mainland tape |
| ASX 200 | −0.92% | Live/near close | Regional laggard |
| Europe | Pre-open at cutoff | Prior displayed closes only | Do not treat DAX 26,299.74 or Stoxx 600 659.24 as current cash prints |
Confirmed: July PPI was flat m/m versus +0.2% expected; core PPI rose 0.2% versus +0.3% expected. The S&P 500 closed at a record and the 10-year ended Thursday near 4.64%. Inference: an immediate Fed hike became less likely, but high long-end yields still cap valuation expansion.
NVDA +0.54% and MU +4.23% joined a tech-led advance. Yet CSCO fell 8.40%, CBRS 11.85%, and optics names weakened after results. Demand is strong; margins, valuation and guidance quality continue to separate winners from losers.
Applied Materials reported record $9.12B revenue, 50.4% non-GAAP gross margin and $3.50 non-GAAP EPS, then traded at $507.63 after hours, −5.03% from the $534.54 close. Strong fundamentals plus a negative reaction equals confirmation risk, not an automatic dip buy.
Nasdaq · mega-cap AI compute/networking · premium-valuation, export and earnings-gap risk
Uncertain direction / thesis: Thursday's $225.30 close retained the prior breakout area while memory and equipment results corroborate demand; a record index and Aug. 26 earnings make chasing unattractive.
Catalyst / evidence: AMAT's DRAM/advanced-packaging outlook, Cisco hyperscaler orders and NVIDIA's Aug. 10 AI-infrastructure financing MOUs. Earnings Aug. 26 are the decisive gate.
Counterargument: very high expectations, concentration and customer financing can amplify downside if growth, supply or margins disappoint.
Entry / confirmation: hold/reclaim $224 after retail sales with semiconductor relative strength; better reward/risk on an orderly $220–224 retest than near the $236.54 52-week high.
Invalidation / downside: close below $216, weak earnings/order commentary, adverse export controls or broad failure of AI leaders.
Key risks: export policy, competition, HBM supply, hyperscaler capex, power constraints, valuation and a large earnings gap.
Nasdaq · large-cap semiconductor equipment · event, China/export and valuation risk · not a short
Uncertain direction / thesis: record fundamentals support the long-term AI-enabler case, but the −5.03% after-hours response says expectations and positioning overwhelm an immediate dip-buy setup.
Evidence / catalyst: $9.12B revenue, 50.4% non-GAAP gross margin, $3.50 non-GAAP EPS, $2.33B free cash flow and Q4 revenue guide $10.25B ± $0.50B.
Counterargument: management expects another strong 2027 and calendar-2026 packaging revenue growth above 70%; the selloff may be temporary profit-taking.
Confirmation: stabilize above roughly $500 then reclaim the $507.63 after-hours reference and eventually $520 with volume; avoid assuming the opening print is support.
Invalidation / downside: a break below $500 with weak breadth, estimate cuts, export restrictions or China/order deterioration.
Key risks: China was 26% of Semiconductor Systems plus AGS revenue, cyclicality, export policy, cleanroom/capacity timing and valuation. No borrow claim.
Nasdaq · newly public high-risk AI chip/cloud company · not a short
Uncertain direction / thesis: Thursday's −11.85% follow-through to $231.01 confirms the earnings reset remains active; raised annual guidance can still fuel sharp rebounds.
Evidence: Q2 revenue $180.11M missed consensus cited by CNBC; adjusted gross margin fell sequentially to 40.6%, while cloud growth and higher FY guidance are positives.
Counterargument: rapidly growing cloud revenue and improving scale can make post-IPO price discovery reverse abruptly.
Confirmation: multiple sessions of stabilization, improving volume behavior, hardware recovery and repeatable margin progress.
Invalidation / downside: avoid stance changes after repeatable beats and margin expansion; downside worsens below the post-result low or on customer slippage.
Key risks: limited public history, customer concentration, manufacturing scale, foundry dependence, competition, dilution and squeeze risk.
Nasdaq · high-risk AI cloud · leverage, capex, concentration and squeeze risk
Uncertain direction / thesis: Thursday's −1.34% to $106.29 was orderly after Wednesday's 19% gap, but capital intensity still makes fresh entry reward/risk weak without a base.
Evidence: Q2 revenue $2.575B and large backlog show demand; Q2 GAAP net loss $626M, net interest $640M and $35–39B FY capex guide show financing sensitivity.
Counterargument: backlog and contracted demand can support continued scale and another momentum leg.
Confirmation: constructive consolidation above $100, funded capex and credible free-cash conversion.
Invalidation / downside: long thesis weakens below the post-earnings gap; avoid stance changes with durable positive free cash flow and lower financing burden.
Key risks: refinancing, dilution, customers, power delivery, utilization, GPU supply and squeezes. No borrow representation.
NYSE · mega-cap peptide leader · C/R/O 83/66/62. Thursday −0.92% to $1,209 invalidated the prior $1,220 hold, though it remains above $1,200. Reclaim $1,220 restores the swing setup; a close below $1,200 downgrades it. Commercial execution is strong, but valuation, access, competition, manufacturing and retatrutide safety/regulatory risk matter.
Nasdaq · high-risk AI systems · C/R/O 78/90/55. +4.12% to $39.16 after Wednesday's +19.02%. The prior paper confirmation remains favorable, but two-day extension worsens entry quality. Wait for a base; below $37.60 then $35 weakens momentum. Cash flow, working capital and export-review risks remain.
NYSE · speculative quantum · C/R/O 78/95/51. −0.49% to $44.98. Q2 revenue evidence is strong, but $120.3M adjusted EBITDA loss and heavy stock compensation keep risk extreme. Sep. 8 Investor Day is the key gate; require a base and funded milestones.
NYSE ADR · large-cap peptide/metabolic · C/R/O 72/72/58. +0.71% to $46.72. A sustained reclaim of $47 plus improving estimates/relative strength would confirm. Competition, pricing/access, trial execution, supply and currency remain risks.
Nasdaq · small-cap clinical biotech · C/R/O 70/96/45. −3.17% to $32.94. No entry without a defined Phase 3/cash-runway thesis. Monitor VK2735 trial design, endpoints, discontinuations, safety, enrollment, regulatory path and financing. A break below $32 worsens the setup; headline gaps can be severe.
Wait for retail sales. Then favor NVDA retest-and-hold behavior over AMAT's opening price discovery. Do not assume AMAT $500 or LLY $1,200 will hold. Avoid CBRS and CRWV momentum chasing; use the first-hour range and breadth.
Only NVDA remains ranked bullish, conditionally. Require $220–224 to hold and reduce size into Aug. 26. LLY needs a $1,220 reclaim; AMAT needs stabilization and a reclaim of post-earnings references.
Prefer cash-generative leaders and enabling tools. NVDA, LLY and AMAT have stronger evidence than venture-like quantum or leveraged AI cloud names, but valuation and event entry still matter. Pure-play quantum and small-cap biotech remain non-core/speculative.